Evaluation of Atacand® (Candesartan) in Daily Medical Practice

A 12-Week Open-Label Non-Interventional Evaluation of Atacand® (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00837720

Enrollment

750

Registered

2009-02-05

Start date

2006-03-31

Completion date

2007-06-30

Last updated

2009-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

hypertension, blood pressure, Atacand®, candesartan

Brief summary

This open label, non-interventional study is to show the efficacy of antihypertensive treatment with Atacand in hypertensive patients. Efficacy is to be evaluated based on the difference in systolic and diastolic blood pressure at baseline and at both follow-up visits.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* a patient with arterial hypertension who has been prescribed Atacand according to physician's judgement, irrespective of the inclusion in the study

Exclusion criteria

* hypersensitivity to candesartan or any other ingredient of Atacand * liver function impairment and/or cholestasis * severe renal insufficiency * woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Systolic and diastolic blood pressure reduction	12 weeks

Secondary

Measure	Time frame
Incidence and reasons of treatment discontinuation	12 weeks
Patient treatment satisfaction (using 5-point answering scale) as the measure of the patient's overall tolerance	12 weeks
Physician overall evaluation of the therapy (using 5-point answering scale)	12 weeks

Outcome results